This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.
COVID-19 Resource Center

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    McMahon Score for Rhabdomyolysis

    Predicts mortality or acute kidney injury (AKI) in rhabdomyolysis patients.

    INSTRUCTIONS

    Use in patients ≥18 years old with rhabdomyolysis (CPK >5,000 U/L within 72 hours of admission). Do not use in patients with pre-existing end-stage renal disease or with elevated CPK due to MI.

    When to Use
    Pearls/Pitfalls
    Why Use

    • Patients ≥18 years old with rhabdomyolysis (CPK >5,000 U/L within 72 hours of admission).

    • Do not use in patients with pre-existing end-stage renal disease or elevated CPK due to MI.

    • Can be used in both traumatic and atraumatic rhabdomyolysis.

    • Not validated for patients who have had renal replacement therapy (RRT) within 24 hours.

    • Not yet prospectively validated (has been retrospectively validated).

    • Uses readily available clinical demographic and laboratory values.

    • More specific than CPK alone at predicting need for RRT (AUROC 0.775 vs 0.631).

    ≤50
    0
    51-70
    +1.5
    71-80
    +2.5
    >80
    +3
    Male
    0
    Female
    +1
    <1.4 mg/dL (124 µmol/L)
    0
    1.4–2.2 mg/dL (124–195 µmol/L)
    +1.5
    >2.2 mg/dL (195 µmol/L)
    +3
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    Yes
    0
    No
    +3
    <4.0 mg/dL (1.0 mmol/L)
    0
    4.0–5.4 mg/dL (1.0-1.4 mmol/L)
    +1.5
    >5.4 mg/dL (1.4 mmol/L)
    +3
    No
    0
    Yes
    +2

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Gearoid M. McMahon

    About the Creator

    Gearoid M. McMahon, MD, MB, BCh, is a nephrologist at Brigham and Women's Hospital in Boston. He is also one of the editors of the popular nephrology resource Renal Fellow Network. Dr. McMahon’s research focuses primarily on acid-base disorders, acute renal failure, glomerular disease, and kidney stones.

    To view Dr. Gearoid M. McMahon's publications, visit PubMed

    Content Contributors
    About the Creator
    Dr. Gearoid M. McMahon
    Content Contributors